<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01514123</url>
  </required_header>
  <id_info>
    <org_study_id>VGX-100-1001</org_study_id>
    <nct_id>NCT01514123</nct_id>
  </id_info>
  <brief_title>Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Open Label, Dose Escalation Study of the VEGF-C Human Monoclonal Antibody VGX-100 Administered by Intravenous Infusion Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circadian Technologies Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Circadian Technologies Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, multi-dose, first-in-human, multicenter, two arm (Arm A: VGX-100&#xD;
      alone; Arm B: VGX-100 co-administered with bevacizumab), open label, dose escalation study in&#xD;
      subjects with advanced or metastatic solid tumors. The study is aimed at evaluating the&#xD;
      safety and establishing the recommended dose of the VEGF-C human monoclonal antibody VGX-100&#xD;
      when administered alone or in combination with bevacizumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 29, 2011</start_date>
  <completion_date type="Actual">November 16, 2017</completion_date>
  <primary_completion_date type="Actual">February 7, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and severity of adverse events including dose limiting toxicities</measure>
    <time_frame>Approximately 16 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response by RECIST criteria</measure>
    <time_frame>Approximately 16 months</time_frame>
    <description>Tumor response assessment will be measured by computated tomography (CT) or Magnetic resonance imaging (MRI) every 8 or 12 weeks throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of VGX-100 alone and co-administered with bevacizumab including Cmax, Cmin, AUC and if feasible half life (t1/2)</measure>
    <time_frame>28 days after the last subject in each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-VGX-100 antibody formation</measure>
    <time_frame>Approximately 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker levels including VEGF-A, VEGF-C, VEGF-D, soluble VEGFR-2, and soluble VEGFR-3</measure>
    <time_frame>Approximately 16 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Neoplasms</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A - VGX-100 alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of VGX-100 monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - VGX-100 plus bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of VGX-100 in combination with escalating doses of bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VGX-100</intervention_name>
    <description>VGX-100 will be administered by IV infusion once every week</description>
    <arm_group_label>Arm A - VGX-100 alone</arm_group_label>
    <arm_group_label>Arm B - VGX-100 plus bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab will be administered by IV infusion once every 2 weeks</description>
    <arm_group_label>Arm B - VGX-100 plus bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Provision of written informed consent&#xD;
&#xD;
          -  Histologically or cytologically documented advanced or metastatic solid tumor that is&#xD;
             refractory to standard treatment, for which no standard therapy is available, or for&#xD;
             which the subject refuses standard therapy&#xD;
&#xD;
          -  Life expectancy &gt; 3 months in the opinion of the investigator&#xD;
&#xD;
          -  ECOG performance status 0 to 1&#xD;
&#xD;
          -  Evaluable OR measurable disease by RECIST 1.1 criteria&#xD;
&#xD;
          -  Agree to the use of effective contraceptive if either male or female of child bearing&#xD;
             potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inadequate venous access&#xD;
&#xD;
          -  Women who are lactating/breastfeeding&#xD;
&#xD;
          -  Women with a positive pregnancy test or who are planning to become pregnant during the&#xD;
             duration of the study&#xD;
&#xD;
          -  Known to be HIV positive, or have chronic hepatitis B or C&#xD;
&#xD;
          -  Major surgical procedure within 6 weeks of Baseline or surgical or other wound that is&#xD;
             not fully healed at Baseline&#xD;
&#xD;
          -  Untreated or symptomatic brain metastasis, known central nervous system metastasis, or&#xD;
             spinal cord compression (except glioblastoma multiforme)&#xD;
&#xD;
          -  Mediastinal or cavitated, or lung mass located near, invading or encasing a major&#xD;
             blood vessel or airway on imaging&#xD;
&#xD;
          -  Squamous cell lung cancer&#xD;
&#xD;
          -  History of or known/suspected gastrointestinal perforation&#xD;
&#xD;
          -  Hemoptysis of &gt;2.5 mL (half a teaspoon) red blood within 28 days of Screening&#xD;
&#xD;
          -  Deep venous thrombosis or history of symptomatic pulmonary thromboembolism within 6&#xD;
             months of Screening&#xD;
&#xD;
          -  Gastrointestinal bleeding requiring medical intervention within 28 days of Screening&#xD;
&#xD;
          -  Receipt of therapeutic concentrations of warfarin or other anticoagulants within 7&#xD;
             days of Screening&#xD;
&#xD;
          -  Receipt of investigational agent(s) for any indication within 28 days of Baseline or 5&#xD;
             half lives, whichever is greater&#xD;
&#xD;
          -  Receipt of the following treatments:&#xD;
&#xD;
               -  Traditional cytotoxics, tyrosine kinase inhibitors or other small molecule&#xD;
                  anti-cancer agents within 21 days&#xD;
&#xD;
               -  Nitrosoureas, mitomycin C, bevacizumab or trastuzumab within 6 weeks&#xD;
&#xD;
               -  Any other therapeutic monoclonal antibodies within 21 days&#xD;
&#xD;
               -  Hormonal therapy (other than gonadal suppression) within 14 days&#xD;
&#xD;
          -  Radiotherapy:&#xD;
&#xD;
               -  to &gt;25% bone marrow&#xD;
&#xD;
               -  to brain within 28 days of baseline&#xD;
&#xD;
               -  other than above within 14 days of baseline&#xD;
&#xD;
          -  Unstable angina, myocardial infarction, transient ischemic events, or stroke within 24&#xD;
             weeks of Screening&#xD;
&#xD;
          -  History of CNS hemorrhage, cerebrovascular hemorrhage, myocardial infarction or&#xD;
             reversible posterior leukoencephalopathy syndrome associated with prior&#xD;
             anti-VEGF/anti-VEGFR therapy&#xD;
&#xD;
          -  Uncontrolled hypertension of ≥ CTCAE Grade 2&#xD;
&#xD;
          -  Proteinuria at Baseline of ≥2+ or 1.0g/24 hours&#xD;
&#xD;
          -  Prior allergic reaction to a monoclonal antibody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Research</last_name>
    <role>Study Director</role>
    <affiliation>Circadian Technologies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Hematology-Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VGX-100</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>VEGF-C</keyword>
  <keyword>First-In-Human</keyword>
  <keyword>Dose Escalation</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Angiogenesis Inhibitors</keyword>
  <keyword>Angiogenesis Modulating Agents</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Oncology</keyword>
  <keyword>Advanced malignancy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

